Utilizer

WHO warns on antibiotic resistance growing rapidly Antibiotic resistance rose in over 40% between 2018-2023. The report (who.int) covers 8 common bacterial pathogens including bacteria causing urinary tract infections (UTI), gastrointestinal infections, sepsis and gonorrhea. Gram-negative bacterial pathogens are posing the greatest threat. Among these, E.coli and K.pnemoniae are the leading drug-resistant bacteria. WHO highligths progress in global AMR surveillance, now involving 104 countries, but emphasizes the urgent need to strengthen infection prevention, diagnosis and treatment systems. UTIs can reliable be detected with bacterial cultures and faster and innovative methods aimed for point of care are coming to the market. #uti #who #AMRsurveillance #antibioticresistance #innovation #Utilizer

UTIs affect millions of people every year — a painful and often recurring condition that too many still face without timely diagnosis or the right treatment. Awareness is growing, but accessibility is key. Every patient deserves fast answers and the right care, no matter where they are. At Utilizer, we’re developing rapid, easy-to-use UTI diagnostics to make accurate testing available everywhere it’s needed — helping patients get the right treatment from the very start. #UTI #Diagnostics #PatientCare #AntimicrobialResistance #AccessibleHealthcare #Innovation

Unlocking the wealth of healthcare data open for our furter understanding of disease and its prevention! #AMR #UTI

🚀 How can healthcare transfer from reactive to proactive? The future lies in prevention and personalised medicine. To get there, we need to shift from qualitative data (questionnaires, low-accuracy measurements) to quantitative, trustworthy data: - Genetics - High-quality laboratory methods - Imaging - Environmental monitoring With AI tools, these data can be combined to identify genetic and environmental risk factors, define high-risk groups, and target prevention and screening programs. The science is ready. The public is ready. Researchers are ready. Now, it’s in the hands of policymakers to prioritise the legal and regulatory frameworks that will unlock this potential. A big thank you to the British Embassy Stockholm and Saba Hussein Gore, PhD & Jacqueline Hjertström for organising such an inspiring event — and to Professor Sir Rory Collins CEO and founder to UK Biobank, Raghib Ali OBE, CEO, Chief Investigator and CMO at Our Future Health, Sonja Eaker Fält, Chairwoman of Biobank Sverige and Patrik Magnusson, Vice head of department MEB at Karolinska Institutet both presenting Biobank Sverige for sharing the incredible progress and vision ahead. We specifically look forward to primary care data being included in the UK Biobank in 2025! #POC diagnostics #UTI #AMR

Big Thank you to the Almi Invest team for a great day of networking and for your ongoing support to help us making a difference! And to fellow entrepreneur for sharing and bringing amazing products and services!

Thank you Almi Invest for arranging a great networking day! It’s always valuable to connect with fellow portfolio companies, exchange insights, and meet potential investors. Our CEO Sofia Bertling made a pitch with full audience about our new innovative point of care UTI test. We truly appreciate investors who act as real partners in driving companies forward. Grateful for the collaboration and support! #Almiinvest #Utilizer #innovation

Great Strategy Day — aligning on priorities, sharpening our activities, and strengthening collaboration. A valuable mix of focus, forward-thinking, and team building! Thank you everyone! #Strategy #Teamwork #Utilizer

🚀 Bringing Rapid UTI Diagnostics to the Point of Care Did you know that Utilizer-ID will be the first approved culture-based UTI test designed for primary care and near-patient settings—not just the microbiology lab? With its unique built-in software, Utilizer-ID delivers results that are fast, clear, and require no expert interpretation. 🔹 Culture-based results in just 5–8 hours (vs. the usual 1–3 days) 🔹 Point-of-care ready — suitable for primary care clinics and urgent care sites 🔹 Supports antibiotic stewardship with evidence-based treatment decisions the same day By moving reliable diagnostics closer to the patient, we can reduce delays, cut down on unnecessary antibiotics, and take a real step forward in the fight against antimicrobial resistance. 👉 Utilizer-ID is here to transform UTI management at the point of care. #PointOfCare #UTIDiagnostics #AntibioticStewardship #HealthcareInnovation #PrimaryCare #RapidTesting #AMR #Diagnostics #PatientCare #ClinicalInnovation #Utilizer

✨ What is effective diagnostics?✨ On September 17, Sofia Bertling represented Swedish LabTech at the Ministry of Health and Social Affairs’ stakeholder meeting on AMR (AntiMicrobial Resistance). The discussion centered on three parallel processes – all with the same goal: keeping antimicrobial resistance as low as possible, both nationally and globally. 🔹 Nationally: Sweden is currently updating its strategy against antimicrobial resistance (2026–2035), to be finalized in November 2026. 🔹 Globally: A new international AMR panel is being formed – jointly by FAO, UNEP, WHO and WOAH – to strengthen knowledge sharing, policy, and One Health collaboration. 🔹 WHO: The global action plan from 2015 (GAP) is being updated ahead of 2026. At the heart of all initiatives lies cross-sector collaboration between human, animal, environmental, and food sectors – to focus efforts where they can have the greatest impact.   🔎 Specifically: ✅ Sweden’s upcoming AMR strategy will include a focus on reliable access to antibiotics and effective diagnostic testing 🚀 Since 2021, Utilizer has been working to bring the Utilizer diagnostic bacterial platform to the market — addressing global needs for an accurate, easy-to-use, and cost-efficient diagnostic test. 👉 Utilizer is proud to contribute to this vital work for the future of health, innovation, and sustainability. #swedishlabtech #socialstyrelsen #Utilizer #AMR